Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.89
+0.18 (1.54%)
Aug 21, 2026, 3:50 PM EDT - Market open

Kura Oncology Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Kura Oncology stock has a consensus rating of "Strong Buy" and an average price target of $32. The average 1-year stock price forecast is 169.13% higher than the current stock price, while the lowest is $15 (+26.16%) and the highest is $76 (+539.19%).

Price Target: $32 (+169.13%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$15$32$28$76
Change+26.16%+169.13%+135.49%+539.19%

Analyst Ratings

The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy111212121212
Buy222222
Hold111111
Sell000000
Strong Sell000000
Total141515151515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Maintains
$15
BuyMaintains$15+26.16%Aug 21, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aAug 13, 2026
Lake Street
Lake Street
Buy
Reiterates
$23
BuyReiterates$23+93.44%Aug 13, 2026
Bank of America Securities
Bank of America Securities
Buy
Reiterates
$31
BuyReiterates$31+160.72%Aug 13, 2026
LifeSci Capital
LifeSci Capital
Buy
Maintains
$28
BuyMaintains$28+135.49%Aug 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
100.01M
from 67.48M
Increased by 48.20%
Revenue Next Year
214.98M
from 100.01M
Increased by 114.96%
EPS This Year
-3.23
from -3.18
EPS Next Year
-2.30
from -3.23
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---53.88M67.48M100.01M
Revenue Growth
----25.24%48.20%
Operating Income
-131.26M-139.87M-165.80M-193.20M-303.63M-306.18M
Net Income
-130.47M-135.84M-152.63M-173.98M-278.67M-289.69M
EPS
-----3.18-3.23
Free Cash Flow
-60.41M-63.67M-63.90M-55.93M-141.73M-258.00M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High139.4M
Avg100.0M
Low89.2M

Revenue Growth

Revenue Growth202620272028
High
106.6%
Avg
48.2%
Low
32.2%

EPS Forecast

EPS202620272028
High-2.98
Avg-3.23
Low-3.48

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-